Evident Vascular offers an advanced IVUS platform that leverages Artificial Intelligence to deliver superior Vascular.
Alleviant Medical focuses on developing a minimally-invasive medical device to treat congestive heart failure. Its proprietary transcatheter technology is designed to create a paradigm shift in the treatment of heart failure by relieving patient symptoms, improving quality of life, and reducing hospital readmissions for over 6 million Americans currently suffering from this disease.
Okami Medical, Inc. is a manufacturer of medical devices specializing in the occlusion of peripheral vessels, primarily through its innovative LOw-profile Braided Occluder (LOBO) system. This device provides interventional physicians with a single solution for occluding various arterial targets, eliminating the need for multiple embolic devices. The LOBO incorporates proprietary HDBRAID technology, which features a unique pore structure that effectively reduces blood flow and accelerates vessel closure. Founded in 2011 and headquartered in Aliso Viejo, California, Okami Medical was established to meet the evolving needs of patients and healthcare providers by developing versatile and intuitive devices that ensure rapid and reliable vessel occlusion under diverse conditions.
iVEAcare focuses on developing innovative neuromodulation therapies aimed at addressing unmet clinical needs in the treatment of chronic diseases. The company creates advanced devices and software that provide targeted electrical stimulation to specific regions of the brain or spinal cord. This technology allows medical professionals to design therapies that are not only more effective but also less invasive than conventional treatments, thereby expanding access to a broader patient population.
Elucent Medical LLC is focused on improving breast cancer treatment processes through innovative technology. Founded in 2014 and headquartered in Brookfield, Wisconsin, the company has developed a wireless marker tag and detection system that enhances the surgical excision of breast abnormalities. This advanced surgical navigation technology allows for real-time data processing, enabling surgeons to accurately locate tumor margins and enhance the precision of procedures. By eliminating the need for metal clips, Elucent Medical's solutions aim to simplify breast cancer treatment, making it more accessible and affordable while helping to preserve patients' breasts during surgery. The company's offerings benefit both healthcare providers and patients by improving overall surgical outcomes.
Evident Vascular offers an advanced IVUS platform that leverages Artificial Intelligence to deliver superior Vascular.
Spyglass Pharma specializes in developing innovative treatments for chronic ophthalmic diseases, leveraging advanced technology to enhance patient care and vision. The company focuses on creating ophthalmic devices and a drug delivery platform that addresses unmet needs in areas such as cataracts and lens replacement surgeries. Its delivery system is designed to be implanted alongside intraocular lenses during standard cataract procedures, allowing surgeons to administer multi-year therapies for chronic conditions. This approach aims to improve the accessibility and affordability of quality eye treatments for patients, ensuring better outcomes in ophthalmic care.
Artelon focuses on the development of innovative synthetic materials for orthopedic soft tissue reconstruction, particularly in tendon and ligament repair. The company provides kinematic reinforcement solutions that enhance the stability and motion of joints, facilitating effective recovery from joint instability. Through its specialized bio-textiles, Artelon aims to assist surgeons in restoring joint strength and function, ultimately improving patient outcomes in orthopedic procedures.
Relievant Medsystems, Inc. is a medical device company focused on developing minimally invasive treatments for chronic axial low back pain. The company has created the Intracept procedure, which specifically targets the basivertebral nerve to alleviate chronic vertebrogenic low back pain. By delivering targeted energy into the spine, the Intracept System effectively blocks the transmission of pain signals, providing patients with a low-risk therapeutic option. Founded in 2004, Relievant is headquartered in Minneapolis, Minnesota, with additional operations in Sunnyvale, California.
Alleviant Medical focuses on developing a minimally-invasive medical device to treat congestive heart failure. Its proprietary transcatheter technology is designed to create a paradigm shift in the treatment of heart failure by relieving patient symptoms, improving quality of life, and reducing hospital readmissions for over 6 million Americans currently suffering from this disease.
Volta Medical is a technology company based in Marseille, France, founded in 2016, that specializes in developing artificial intelligence software for interventional cardiology. The company focuses on aiding cardiologists in the treatment of atrial fibrillation, the most common cardiac arrhythmia. Volta Medical's flagship product utilizes advanced AI algorithms to analyze electrograms and guide mapping catheters during cardiac procedures. This software assists interventional cardiologists by providing real-time insights and step-by-step guidance, enhancing their ability to make informed decisions during patient-specific medical interventions. The company aims to improve the effectiveness of cardiac procedures and the overall management of atrial fibrillation through innovative technological solutions.
Nyra Medical is focused on creating innovative transcatheter heart valve repair technology aimed at treating mitral regurgitation. The company's device is designed to address the leaflets of heart valves while preserving the natural geometry of the mitral valve. By utilizing a proprietary implant, Nyra Medical's technology enables patients to achieve consistent correction of valve regurgitation, improving their overall heart function.
Cleerly is a healthcare company whose mission is to create digital care pathways to prevent heart attacks. The company develops a new standard for coronary artery disease by integrating quality clinical science with the latest-generation AI, in order to offer actionable clinical insights to every stakeholder in the heart care pathway. Through these data-driven solutions, the company aims to provide a comprehensive solution for cardiovascular disease evaluation that offers value to the healthcare system and improves heart health for patients at risk of heart attacks.
Moxe Health specializes in facilitating the bi-directional exchange of clinical data between health plans and provider systems through its innovative clinical data integration platform. The company offers a range of services including risk adjustment, claims denial management, clinical summaries, administrative notifications, and care gap management. By creating an interactive network, Moxe ensures that health systems and health plans can share medical records and crucial patient insights quickly and efficiently, without disrupting clinicians' existing workflows. The platform supports the transition to value-based care by providing automated solutions that enhance access to essential information, allowing organizations to leverage their investments in population health and analytics effectively. Moxe's commitment to neutrality in data connectivity further enhances its value proposition in the healthcare industry.
Apella is an artificial intelligence startup focused on enhancing surgical procedures through advanced healthcare technology. Founded in 2019 and headquartered in San Francisco, California, the company develops systems that utilize AI, computer vision, and modern communication to digitize operating rooms. By collecting data from these environments via sensors, Apella analyzes the information to provide insights that can improve surgical quality, streamline operations, and aid in training and real-time decision-making for medical staff. Its innovative approach aims to elevate surgery outcomes and optimize the overall efficiency of healthcare delivery.
Cleerly is a healthcare company whose mission is to create digital care pathways to prevent heart attacks. The company develops a new standard for coronary artery disease by integrating quality clinical science with the latest-generation AI, in order to offer actionable clinical insights to every stakeholder in the heart care pathway. Through these data-driven solutions, the company aims to provide a comprehensive solution for cardiovascular disease evaluation that offers value to the healthcare system and improves heart health for patients at risk of heart attacks.
GPB Scientific is a biotechnology company that markets its technology to life sciences companies and research establishments. The company has accumulated an extensive portfolio of patents and know-how utilizing microchip technology for size-based enrichment and/or for affinity-based cell capture. The company was founded in 2002 and headquartered in Richmond, Virginia.
Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.
Spyglass Ophthalmics develops ophthalmic devices intended to improve vision and eye care of patients. Spyglass' devices address unmet needs in cataract, lens replacement, surgery, and other chronic ophthalmic diseases, enabling patients to get quality eye treatment at an affordable cost.
Relievant Medsystems, Inc. is a medical device company focused on developing minimally invasive treatments for chronic axial low back pain. The company has created the Intracept procedure, which specifically targets the basivertebral nerve to alleviate chronic vertebrogenic low back pain. By delivering targeted energy into the spine, the Intracept System effectively blocks the transmission of pain signals, providing patients with a low-risk therapeutic option. Founded in 2004, Relievant is headquartered in Minneapolis, Minnesota, with additional operations in Sunnyvale, California.
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.
GPB Scientific is a biotechnology company that markets its technology to life sciences companies and research establishments. The company has accumulated an extensive portfolio of patents and know-how utilizing microchip technology for size-based enrichment and/or for affinity-based cell capture. The company was founded in 2002 and headquartered in Richmond, Virginia.
Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.
Vesper Medical is committed to developing safe, efficacious and easy-to-use products for patients with deep venous disease and the physicians who treat them. The company's core technology, the Vesper DUO Venous Stent System, is purpose-built for venous stenting, with an unmatched combination of strength and flexibility designed to meet the multiple anatomical challenges presented by vein mechanics. Vesper Medical is advancing the treatment of deep venous disease by creating a highly differentiated, purpose-built venous stent portfolio that addresses the multiple anatomical challenges presented by the iliac and femoral veins. It also develops minimally- invasive peripheral vascular products. Vesper Medical was founded in 2016 and is headquartered in Wayne, PA, USA.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.